VERU
VERU
NASDAQ · Pharmaceuticals

Veru Inc

$2.12
+0.06 (+2.91%)
As of Nov 7, 2:40 AM ET ·
Financial Highlights (FY 2026)
Revenue
20.16M
Net Income
-45,130,344
Gross Margin
34.7%
Profit Margin
-223.9%
Rev Growth
-34.9%
D/E Ratio
—
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 34.7% 34.7% 54.7% 54.7%
Operating Margin -218.6% -196.7% 29.3% 32.3%
Profit Margin -223.9% -212.7% 24.9% 21.7%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 20.16M 30.98M 6.59M 7.88M
Gross Profit 6.99M 10.74M 3.61M 4.31M
Operating Income -44,072,366 -60,948,262 1.93M 2.55M
Net Income -45,130,344 -62,411,354 1.64M 1.71M
Gross Margin 34.7% 34.7% 54.7% 54.7%
Operating Margin -218.6% -196.7% 29.3% 32.3%
Profit Margin -223.9% -212.7% 24.9% 21.7%
Rev Growth -34.9% -34.9% +19.2% -4.5%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 0 0 6.76M 7.86M
Total Equity — — 15.00M 16.14M
D/E Ratio — — 0.45 0.49
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -43,751,974 -63,866,587 3.19M 3.50M
Free Cash Flow — — 1.30M 1.17M